Should I buy or sell Nevro stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last twelve months. There are currently 1 sell rating, 11 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NVRO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVRO, but not buy additional shares or sell existing shares. View NVRO analyst ratings or view top-rated stocks .

What is Nevro's stock price target for 2024?

13 analysts have issued 12-month target prices for Nevro's shares. Their NVRO share price targets range from $14.00 to $40.00. On average, they predict the company's stock price to reach $21.23 in the next twelve months. This suggests a possible upside of 75.9% from the stock's current price. View analysts price targets for NVRO or view top-rated stocks among Wall Street analysts .

How have NVRO shares performed in 2024?

Nevro's stock was trading at $21.52 at the beginning of the year. Since then, NVRO shares have decreased by 43.9% and is now trading at $12.07. View the best growth stocks for 2024 here .

When is Nevro's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our NVRO earnings forecast .

How were Nevro's earnings last quarter?

Nevro Corp. (NYSE:NVRO) posted its earnings results on Wednesday, February, 21st. The medical equipment provider reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.35. The medical equipment provider had revenue of $116.18 million for the quarter, compared to analyst estimates of $115.93 million. Nevro had a negative trailing twelve-month return on equity of 30.22% and a negative net margin of 21.69%.

What ETFs hold Nevro's stock?

ETFs with the largest weight of Nevro (NYSE:NVRO) stock in their portfolio include Alger Weatherbie Enduring Growth ETF (AWEG) and iShares Neuroscience and Healthcare ETF (IBRN) . Fidelity Digital Health ETF (FDHT) .

What guidance has Nevro issued on next quarter's earnings?

Nevro updated its first quarter 2024 earnings guidance on Wednesday, February, 21st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $97.0 million-$99.0 million, compared to the consensus revenue estimate of $98.7 million.

What is D. Keith Grossman's approval rating as Nevro's CEO?

9 employees have rated Nevro Chief Executive Officer D. Keith Grossman on Glassdoor.com . D. Keith Grossman has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Nevro own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T) , NVIDIA (NVDA) , AbbVie (ABBV) , Walt Disney (DIS) , General Electric (GE) , Micron Technology (MU) , Gilead Sciences (GILD) , Advanced Micro Devices (AMD) , Adobe (ADBE) and Intuitive Surgical (ISRG) .

How do I buy shares of Nevro?

Shares of NVRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSE:NVRO

Nevro (NVRO) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free NVRO Stock Alerts

$12.32

+0.03 (+0.24%)

(As of 04:35 PM ET)

Compare

Today's Range: $12.05
▼
$12.38
50-Day Range: $12.29
▼
$17.40
52-Week Range: $12.05
▼
$39.67

Volume: 407,596 shs
Average Volume: 476,623 shs
Market Capitalization: $451.90 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $21.23

Get Nevro alerts:

Nevro MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 75.9% Upside
$21.23 Price Target
Short Interest: Bearish
12.14% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.28
Based on 8 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.54) to ($2.23) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.75 out of 5 stars

Medical Sector

617th out of 914 stocks

Surgical & Medical Instruments Industry

62nd out of 94 stocks

4.0

Analyst's Opinion

Consensus Rating
Nevro has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 11 hold ratings, and 1 sell rating.
Amount of Analyst Coverage
Nevro has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
12.14% of the float of Nevro has been sold short.
Short Interest Ratio / Days to Cover
Nevro has a short interest ratio ("days to cover") of 8.6.
Change versus previous month
Short interest in Nevro has recently increased by 0.24%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Nevro does not currently pay a dividend.
Dividend Growth
Nevro does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NVRO.

1.5

News and Social Media Coverage

News Sentiment
Nevro has a news sentiment score of -0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for Nevro this week, compared to 3 articles on an average week.
Search Interest
1 people have searched for NVRO on MarketBeat in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Nevro insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.00% of the stock of Nevro is held by insiders.
Percentage Held by Institutions
95.52% of the stock of Nevro is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Nevro are expected to grow in the coming year, from ($2.54) to ($2.23) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Nevro is -4.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Nevro is -4.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Nevro has a P/B Ratio of 1.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Nevro Stock (NYSE:NVRO)

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.

NVRO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NVRO Stock News Headlines

April 17, 2024 | finance.yahoo.com

Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024

April 17, 2024 | prnewswire.com

Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 16, 2024 | americanbankingnews.com

Nevro (NYSE:NVRO) Given New $16.00 Price Target at Royal Bank of Canada

April 13, 2024 | americanbankingnews.com

Mizuho Lowers Nevro (NYSE:NVRO) Price Target to $16.00

April 12, 2024 | americanbankingnews.com

Nevro Corp. (NYSE:NVRO) Receives Consensus Rating of "Hold" from Analysts

April 9, 2024 | americanbankingnews.com

Nevro (NYSE:NVRO) PT Lowered to $14.00 at Wells Fargo & Company

April 3, 2024 | benzinga.com

Where Nevro Stands With Analysts

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 25, 2024 | finanznachrichten.de

EnviroGold Global Limited: NVRO announces Management Changes and provides an update on its Proprietary Leaching Technology Commercialization

March 11, 2024 | finance.yahoo.com

NVRO Mar 2024 20.000 put

February 28, 2024 | prnewswire.com

Nevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral Screw

February 27, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Nevro Corp (NVRO), Karuna Therapeutics (KRTX) and Gilead Sciences (GILD)

February 26, 2024 | markets.businessinsider.com

Nevro Corp: Hold Rating Affirmed Amidst Mixed Performance and Market Uncertainty

February 23, 2024 | realmoney.thestreet.com

Nevro just downgraded at Oppenheimer, here's why

February 22, 2024 | finanznachrichten.de

Nevro Corp.: Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results

February 22, 2024 | fool.com

Why Nevro Stock Lagged the Market on Thursday

February 22, 2024 | markets.businessinsider.com

Hold Rating on Nevro Corp Amid Modest Growth and Cautious 2024 Outlook

February 22, 2024 | markets.businessinsider.com

Analyst Scoreboard: 4 Ratings For Nevro

February 22, 2024 | finance.yahoo.com

Nevro Corp. (NYSE:NVRO) Q4 2023 Earnings Call Transcript

February 22, 2024 | washingtonpost.com

Nevro: Q4 Earnings Snapshot

February 21, 2024 | msn.com

Nevro GAAP EPS of -$0.25 beats by $0.24, revenue of $116.17M beats by $0.17M

February 21, 2024 | finance.yahoo.com

Nevro Corp (NVRO) Reports Modest Revenue Growth Amidst Strategic Shifts

February 21, 2024 | finance.yahoo.com

Nevro (NVRO) Reports Q4 Loss, Tops Revenue Estimates

February 21, 2024 | prnewswire.com

Nevro Enters Into Cooperation Agreement With Engaged Capital

February 21, 2024 | prnewswire.com

Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results

February 20, 2024 | markets.businessinsider.com

Nevro is about to announce its earnings — here's what Wall Street expects

See More Headlines

Receive NVRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nevro and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/21/2024
Today: 4/18/2024
Next Earnings (Confirmed): 5/07/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NYSE:NVRO
CUSIP: N/A
CIK: 1444380
Web: www.nevro.com
Phone: (650) 251-0005
Fax: N/A
Employees: 1,215
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $21.23
High Stock Price Target: $40.00
Low Stock Price Target: $14.00
Potential Upside/Downside: +72.3%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 13 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.57)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-92,210,000.00
Net Margins: -21.69%
Pretax Margin: -23.02%
Return on Equity: -30.22%
Return on Assets: -15.17%

Debt

Debt-to-Equity Ratio: 0.72
Current Ratio: 6.37
Quick Ratio: 4.94

Sales & Book Value

Annual Sales: $425.17 million
Price / Sales: 1.06
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $8.10 per share
Price / Book: 1.52

Miscellaneous

Outstanding Shares: 36,680,000
Free Float: 35,581,000
Market Cap: $451.90 million
Optionable: Optionable
Beta: 0.89

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Mr. Roderick H. MacLeod (Age 57)
Senior VP & CFO
Comp: $729.61k
Mr. Kashif Rashid (Age 50)
Senior VP, General Counsel & Corporate Secretary
Comp: $703.35k
Mr. Kevin R. Thornal (Age 50)
President, CEO & Director
Mr. Richard B. Carter (Age 53)
Chief Accounting Officer
Mr. Christofer Christoforou (Age 54)
Senior Vice President of Technical Operations
Comp: $367.4k
Geeta Kaveti
VP and Chief Compliance & Privacy Officer
Mr. Jon R. Shear
Senior Vice President of Corporate Development
Meredith Vornholt
Vice President of Global Marketing
Ms. Shana D. Ross M.B.A.
Senior VP & Chief of Human Resources Officer
Dr. David Caraway M.D. (Age 67)
Ph.D., Senior VP & Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NVRO Stock Analysis - Frequently Asked Questions

Should I buy or sell Nevro stock right now?: 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last twelve months. There are currently 1 sell rating, 11 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NVRO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVRO, but not buy additional shares or sell existing shares.
View NVRO analyst ratings or view top-rated stocks.
What is Nevro's stock price target for 2024?: 13 analysts have issued 12-month target prices for Nevro's shares. Their NVRO share price targets range from $14.00 to $40.00. On average, they predict the company's stock price to reach $21.23 in the next twelve months. This suggests a possible upside of 75.9% from the stock's current price.
View analysts price targets for NVRO or view top-rated stocks among Wall Street analysts.
How have NVRO shares performed in 2024?: Nevro's stock was trading at $21.52 at the beginning of the year. Since then, NVRO shares have decreased by 43.9% and is now trading at $12.07.
View the best growth stocks for 2024 here.
When is Nevro's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our NVRO earnings forecast.
How were Nevro's earnings last quarter?: Nevro Corp. (NYSE:NVRO) posted its earnings results on Wednesday, February, 21st. The medical equipment provider reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.35. The medical equipment provider had revenue of $116.18 million for the quarter, compared to analyst estimates of $115.93 million. Nevro had a negative trailing twelve-month return on equity of 30.22% and a negative net margin of 21.69%.
What ETFs hold Nevro's stock?: ETFs with the largest weight of Nevro (NYSE:NVRO) stock in their portfolio include Alger Weatherbie Enduring Growth ETF (AWEG) and iShares Neuroscience and Healthcare ETF (IBRN).Fidelity Digital Health ETF (FDHT).

What guidance has Nevro issued on next quarter's earnings?: Nevro updated its first quarter 2024 earnings guidance on Wednesday, February, 21st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $97.0 million-$99.0 million, compared to the consensus revenue estimate of $98.7 million.
What is D. Keith Grossman's approval rating as Nevro's CEO?: 9 employees have rated Nevro Chief Executive Officer D. Keith Grossman on Glassdoor.com. D. Keith Grossman has an approval rating of 68% among the company's employees.
What other stocks do shareholders of Nevro own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), Walt Disney (DIS), General Electric (GE), Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Adobe (ADBE) and Intuitive Surgical (ISRG).
How do I buy shares of Nevro?: Shares of NVRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:NVRO) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Nevro (NVRO) Stock Price, News & Analysis

Nevro MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Nevro Stock (NYSE:NVRO)

NVRO Stock Price History

NVRO Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

NVRO Stock Analysis - Frequently Asked Questions

Overall MarketRank^™